Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study

This study has been completed.
Sponsor:
Collaborator:
Thoratec Corporation
Information provided by (Responsible Party):
Nicholas Haglund, MD, University of Nebraska
ClinicalTrials.gov Identifier:
NCT01571037
First received: May 6, 2011
Last updated: February 28, 2014
Last verified: February 2014

May 6, 2011
February 28, 2014
April 2012
February 2013   (final data collection date for primary outcome measure)
Safety [ Time Frame: 12 and 24 hours ] [ Designated as safety issue: Yes ]
  1. Arrhythmias:

    • Atrial
    • Ventricular
  2. 'Sustained' hypotension
  3. Hypersensitivity reaction to milrinone
Same as current
Complete list of historical versions of study NCT01571037 on ClinicalTrials.gov Archive Site
  • Efficacy - Hemodynamic [ Time Frame: 30, 60 minutes, then every 4 hours thereafter ] [ Designated as safety issue: No ]

    Invasive Hemodynamic pulmonary catheter:

    • PAS, PAD, mPAP, RA pressures, PCWP, CI, RVSWi (calculated), TPG, PVR, and SvO2
  • Efficacy - Echocardiographic [ Time Frame: Pre op Echocardiography, intraoperative TEE (before and after inhaled milrinone) and postoperative Echocardiography within 48 hours of milrinone initiation ] [ Designated as safety issue: No ]

    Echocardiographic

    • RV dimensions
    • RV systolic functional assessment
    • Tricuspid valve regurgitation
    • Pulmonary Vascular resistance
Same as current
Not Provided
Not Provided
 
Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study
Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study

Right ventricular (RV) failure occurs in an estimated 5-41% of cases involving left ventricular assist device (LVAD) implantation and has been shown to adversely affect peri-operative morbidity and mortality. Current therapies to improve RV dysfunction pre and post-operatively are limited. Inhaled milrinone has been shown in several small human studies to be safely tolerated and provide favorable effects on pulmonary hemodynamics.

Study Hypothesis: Delivery of inhaled milrinone, a phosphodiesterase III inhibitor, may provide pulmonary artery vasodilation and therefore improved RV function in patients with end stage heart failure receiving HeartMate II LVAD as a bridge to cardiac transplantation or as destination therapy.

Specifically, we aim to:

  • demonstrate safety of inhaled milrinone in this patient cohort
  • demonstrate efficacy of inhaled milrinone in this patient cohort
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • End Stage Heart Disease
  • Right Ventricular Dysfunction
  • Drug: Inhaled, nebulized, Milrinone
    1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation.
  • Drug: inhaled nebulized milrinone
    0.5 mg/ml inhaled nebulized milrinone deliver at 12 ml/hr continuously until either 24 hours or extubated.
inhaled nebulized Milrinone

Drug: Inhaled, nebulized, Milrinone

1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation.

Interventions:
  • Drug: Inhaled, nebulized, Milrinone
  • Drug: inhaled nebulized milrinone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
February 2014
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. For BTT candidates:

    • Must be an approved candidate for heart transplantation according to institutional policy
  2. For DT candidates:

    • Patients with New York Heart Association (NYHA) class IV symptoms that have failed to respond to maximal medical therapy including beta blocker and angiotensin converting enzyme inhibitors if tolerated for at least 45 of 60 days, OR dependence on continuous inotropic therapy for 14 days OR dependence on intra-aortic balloon pump (IABP) for 7 days
    • Left ventricular ejection fraction (LVEF) < 25%
    • Patients with functional limitations on cardiopulmonary stress testing with a peak oxygen consumption of ≤ 14 ml/kg/min unless balloon pump or inotrope dependent or physically unable to perform the test.
    • Patients not deemed to be a heart transplant candidate after evaluation
    • Must have mean PAP > 25 mmHg by pulmonary catheter indices pre-operatively (within 72 hrs) and/or a PVR > 3 Woods units (WU).
    • Age ≥ 19 years old (in the state of Nebraska, an individual must be ≥ 19 years old to legally provide consent as compared to age ≥ 18 in most other states)
    • Signed informed consent

Exclusion Criteria:

  • Age < 19 years old
  • Pregnancy or current breast feeding
  • Undergoing cardiac transplantation without implantation of mechanical assist device
  • Documented medical allergy to milrinone
  • Failure to meet inclusion criteria for LVAD implantation for BTT or DT indications
Both
19 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01571037
195-11-FB
Yes
Nicholas Haglund, MD, University of Nebraska
University of Nebraska
Thoratec Corporation
Principal Investigator: Nicholas A Haglund, MD University of Nebraska
University of Nebraska
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP